Posted On: 02/19/2015 10:53:32 AM
Post# of 30065
Re: biotechexpert #16948
Revenue will move the stock price. Here are three sources of revenue in 2015:
1) Lympro revenue from clinical trials,
2) Lympro revenue from AD Doctors/Patients after CLIA, and
3) MSPrecise revenue once the diagnostic has been validated in lab.
We will get revenue from all three of these sources in 2015. When and how much are not clear yet, hence the stall in stock price. But in the coming weeks Gerald could start giving us more guidance as the picture becomes clearer. He may put out some estimates to get institutional investors interested.
I can see Gerald going on a "road show" in April or May visiting institutional investors prior to an IPO up list in May or June. That is my best guess as to what will drive AMBS to higher ground.
But preceding the build up to the IPO up list there are other catalysts that will add momentum: Eltoprazine grant and start up of Phase 2b trial, announcement of another MANF orphan indication approval, more Lympro contracts, Parkinsons data announced that they're sitting on now, etc. etc...
I think management is highly motivated to get the stock price above .20 cents by May so AMBS can RS, IPO, and up list by June. The kettle has taken awhile to heat up, but it is boiling now.
1) Lympro revenue from clinical trials,
2) Lympro revenue from AD Doctors/Patients after CLIA, and
3) MSPrecise revenue once the diagnostic has been validated in lab.
We will get revenue from all three of these sources in 2015. When and how much are not clear yet, hence the stall in stock price. But in the coming weeks Gerald could start giving us more guidance as the picture becomes clearer. He may put out some estimates to get institutional investors interested.
I can see Gerald going on a "road show" in April or May visiting institutional investors prior to an IPO up list in May or June. That is my best guess as to what will drive AMBS to higher ground.
But preceding the build up to the IPO up list there are other catalysts that will add momentum: Eltoprazine grant and start up of Phase 2b trial, announcement of another MANF orphan indication approval, more Lympro contracts, Parkinsons data announced that they're sitting on now, etc. etc...
I think management is highly motivated to get the stock price above .20 cents by May so AMBS can RS, IPO, and up list by June. The kettle has taken awhile to heat up, but it is boiling now.
(0)
(0)
